1
|
Codony F, Barreto L, Agustí G, Asensio D. Understanding the reaction balances behind the viability PCR protocols based on photoreactive dyes. J Microbiol Methods 2023; 209:106737. [PMID: 37182808 DOI: 10.1016/j.mimet.2023.106737] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 05/11/2023] [Accepted: 05/11/2023] [Indexed: 05/16/2023]
Abstract
Viability-PCR (vPCR) protocols are mainly based on photo-reactive dyes impermeant to intact cell membranes. The absence of cell barriers allows the reagent's interaction with the genetic material after a short incubation period. By light-induced reaction, DNA becomes the unsuitable mould for the polymerases and thus cannot be amplified and detected by PCR. General rules and consensus exist on critical aspects of successful vPCR protocol development. However, the understanding of the vPCR reaction concerning how much reagent is really effective or the proper amount of light has been poorly studied. The convenience of using 600 times more dye than bases pairs exist suggests that although these dyes are DNA intercalating reagents, many organic molecules can adsorb it. Concerning light, no exact references exist about how much energy is needed to activate the azide group of reagents such as propidium monoazide. Therefore, it cannot be calculated in terms of energy how much light needs a vPCR protocol. The general rule is to provide reagents and energy in excess. This work provides different responses (based on experimental results) to both questions, which can contribute to a better understanding of the theoretical basis of vPCR protocols.
Collapse
Affiliation(s)
- F Codony
- Laboratori d'Aigües de Mataro, carrer Hèl·lade, 17-19, 08304 Mataró, Spain.
| | - L Barreto
- Department of Quality Control, Reactivos para Diagnóstico, S.L., Polígono Industrial Mas d'En Cisa, Calle Josep Tura 9 H, 08181 Sentmenat, Barcelona, Spain
| | - G Agustí
- Department of Quality Control, Reactivos para Diagnóstico, S.L., Polígono Industrial Mas d'En Cisa, Calle Josep Tura 9 H, 08181 Sentmenat, Barcelona, Spain
| | - D Asensio
- Department of Quality Control, Reactivos para Diagnóstico, S.L., Polígono Industrial Mas d'En Cisa, Calle Josep Tura 9 H, 08181 Sentmenat, Barcelona, Spain
| |
Collapse
|
2
|
Terrones-Fernandez I, Casino P, López A, Peiró S, Ríos S, Nardi-Ricart A, García-Montoya E, Asensio D, Marqués AM, Castilla R, Gamez-Montero PJ, Piqué N. Improvement of the Pour Plate Method by Separate Sterilization of Agar and Other Medium Components and Reduction of the Agar Concentration. Microbiol Spectr 2023; 11:e0316122. [PMID: 36625633 PMCID: PMC9927588 DOI: 10.1128/spectrum.03161-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 12/12/2022] [Indexed: 01/11/2023] Open
Abstract
Although the pour plate method is widely employed in microbiological quality control, it has certain drawbacks, including having to melt the culture medium before seeding. In this study, the preparation of the culture medium was modified by using a lower concentration of agar (10 g/L), which was separated from the nutrients during sterilization. The new protocol was assessed in media frequently used in microbiological quality control of food, cosmetics, and pharmaceutical products, with tryptic soy agar (TSA), Sabouraud 4% dextrose agar (SDA), and violet red bile glucose agar (VRBG). In comparison with the conventionally produced media, the modifications significantly improved the growth of Saccharomyces cerevisiae in SDA, Staphylococcus aureus, Salmonella enterica subsp. enterica serovar Typhimurium, and Candida albicans in TSA and Escherichia coli ATCC 8739 and ATCC 25922 and S. Typhimurium in VRBG. The modified VRBG was also more selective for Pseudomonas aeruginosa. Regarding physicochemical properties, a significantly lower pH was observed in TSA and VRBG and lower strength values in TSA. Sterilizing agar separately from the other components of the medium and reducing the agar concentration to 10 g/L can improve microorganism growth and enhance the selectivity of differential media in the pour plate method. These modifications could facilitate the automation of this culture technique. IMPORTANCE In the era of rapid microbiological methods, there is a need to improve long-established culture techniques. Drawbacks of the pour plate method include having to melt each medium separately before seeding. For this technique, we demonstrate that separating the agar from the other components of commonly used media during sterilization and reducing the agar concentration to 10 g/L can enhance microbial growth. The new protocol could have advantages in routine laboratory practice because less agar is required and the same molten agar suspension can be used to prepare different media. Moreover, these modifications could facilitate the automation of the pour plate method.
Collapse
Affiliation(s)
- I. Terrones-Fernandez
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD), Barcelona, Catalonia, Spain
- CATMech. Department of Fluid Mechanics, Universitat Politecnica de Catalunya, Terrassa, Catalonia, Spain
| | - P. Casino
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD), Barcelona, Catalonia, Spain
| | - A. López
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD), Barcelona, Catalonia, Spain
| | - S. Peiró
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD), Barcelona, Catalonia, Spain
| | - S. Ríos
- Department of Genetics, Microbiology and Statistics, Biology Faculty, Universitat de Barcelona, Barcelona, Catalonia, Spain
- Department of Biochemistry and Biotechnology, Human Nutrition Unit, Universitat Rovira i Virgili, Reus, Catalonia, Spain
| | - A. Nardi-Ricart
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Catalonia, Spain
| | - E. García-Montoya
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Catalonia, Spain
- Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology Research Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Catalonia, Spain
| | - D. Asensio
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD), Barcelona, Catalonia, Spain
| | - A. M. Marqués
- Microbiology Section, Department of Biology, Healthcare and Environment, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain
| | - R. Castilla
- CATMech. Department of Fluid Mechanics, Universitat Politecnica de Catalunya, Terrassa, Catalonia, Spain
| | - P. J. Gamez-Montero
- CATMech. Department of Fluid Mechanics, Universitat Politecnica de Catalunya, Terrassa, Catalonia, Spain
| | - N. Piqué
- Microbiology Section, Department of Biology, Healthcare and Environment, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain
- Institut de Recerca en Nutrició i Seguretat Alimentària de la UB (INSA-UB), Universitat de Barcelona, Barcelona, Catalonia, Spain
| |
Collapse
|
3
|
Torrico M, Casino P, López A, Peiró S, Ríos M, Ríos S, Montes MJ, Guillén C, Nardi-Ricart A, García-Montoya E, Asensio D, Marqués AM, Piqué N. Improvement of Mueller-Kauffman Tetrathionate-Novobiocin (MKTTn) enrichment medium for the detection of Salmonella enterica by the addition of ex situ-generated tetrathionate. J Microbiol Methods 2022; 199:106524. [PMID: 35732231 DOI: 10.1016/j.mimet.2022.106524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 06/15/2022] [Accepted: 06/15/2022] [Indexed: 12/27/2022]
Abstract
The detection of Salmonella in food is based on the use of a selective enrichment broth such as Muller-Kauffman Tetrathionate-Novobiocin (MKTTn), in which tetrathionate plays a key role by providing Salmonella with a growth advantage. As sodium tetrathionate is unstable, it is generated in situ by the addition of iodine (Lugol's solution) before seeding. This step is cumbersome as the solution is easily spilled, compromising the performance of the medium and hindering the work of technicians. The aim of this study was to optimize MKTTn broth by generating tetrathionate ex situ through an external reaction between iodine and thiosulphate followed by lyophilization. Quality control procedures were performed to compare the modified and original media, testing pure productivity (enrichment with 50-120 CFU of Salmonella Thyphimurim ATCC 14028 and Salmonella Enteritidis ATCC 13076 and plating on Xylose Lysine Deoxycholate agar, XLD), mixed productivity (50-120 CFU of Salmonella strains and Pseudomonas aeruginosa and Escherichia coli at ≥104 CFU and XLD plating) and selectivity (≥104 CFU of P. aeruginosa and Enterococcus faecalis and plating on Tryptone Casein Soy agar, TSA). The modified MKTTn medium (S/L) performed comparably with the original medium in terms of growth of both Salmonella strains (>300 colonies in XLD), alone or with P. aeruginosa and E. coli. Quantitative assays showed no statistically significant differences in the number of colonies grown on XLD after 10-5 dilution (p = 0.7015 with S. Thyphimurim ATCC 14028 and p = 0.2387 with S. enteritidis ATCC 13076; ANOVA test). MKTTn medium (S/L) was also selective against E. coli (≤100 colonies) and E. faecalis (<10 colonies). These results suggest that adding tetrathionate as a lyophilisate (S/L) is a feasible alternative to the use of Lugol's solution for the preparation of MKTTn enrichment broth and does not affect the properties of the medium.
Collapse
Affiliation(s)
- M Torrico
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD). Josep Tura, 9H, polígon industrial Mas d'en Cisa, 08181 Sentmenat, Barcelona, Catalonia, Spain
| | - P Casino
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD). Josep Tura, 9H, polígon industrial Mas d'en Cisa, 08181 Sentmenat, Barcelona, Catalonia, Spain
| | - A López
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD). Josep Tura, 9H, polígon industrial Mas d'en Cisa, 08181 Sentmenat, Barcelona, Catalonia, Spain
| | - S Peiró
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD). Josep Tura, 9H, polígon industrial Mas d'en Cisa, 08181 Sentmenat, Barcelona, Catalonia, Spain; Microbiology Section, Department of Biology, Healthcare and Environment, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain
| | - M Ríos
- Department of Genetics, Microbiology and Statistics, Biology Faculty, Universitat de Barcelona, Barcelona, Catalonia, Spain
| | - S Ríos
- Department of Genetics, Microbiology and Statistics, Biology Faculty, Universitat de Barcelona, Barcelona, Catalonia, Spain; Department of Biochemistry and Biotechnology, Human Nutrition Unit, Universitat Rovira i Virgili, Reus, Catalonia, Spain
| | - M J Montes
- Microbiology Section, Department of Biology, Healthcare and Environment, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain
| | - C Guillén
- Microbiology Section, Department of Biology, Healthcare and Environment, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain
| | - A Nardi-Ricart
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Catalonia, Spain
| | - E García-Montoya
- Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Catalonia, Spain; Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology research group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Catalonia, Spain
| | - D Asensio
- Department of Quality Control, Reactivos para Diagnóstico, S.L. (RPD). Josep Tura, 9H, polígon industrial Mas d'en Cisa, 08181 Sentmenat, Barcelona, Catalonia, Spain
| | - A M Marqués
- Microbiology Section, Department of Biology, Healthcare and Environment, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain
| | - N Piqué
- Microbiology Section, Department of Biology, Healthcare and Environment, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona (UB), Barcelona, Catalonia, Spain; Institut de Recerca en Nutrició i Seguretat Alimentària de la UB (INSA-UB), Universitat de Barcelona, Barcelona, Catalonia, Spain.
| |
Collapse
|
4
|
Margalef O, Sardans J, Fernández-Martínez M, Molowny-Horas R, Janssens IA, Ciais P, Goll D, Richter A, Obersteiner M, Asensio D, Peñuelas J. Global patterns of phosphatase activity in natural soils. Sci Rep 2017; 7:1337. [PMID: 28465504 PMCID: PMC5431046 DOI: 10.1038/s41598-017-01418-8] [Citation(s) in RCA: 106] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Accepted: 03/28/2017] [Indexed: 11/25/2022] Open
Abstract
Soil phosphatase levels strongly control the biotic pathways of phosphorus (P), an essential element for life, which is often limiting in terrestrial ecosystems. We investigated the influence of climatic and soil traits on phosphatase activity in terrestrial systems using metadata analysis from published studies. This is the first analysis of global measurements of phosphatase in natural soils. Our results suggest that organic P (Porg), rather than available P, is the most important P fraction in predicting phosphatase activity. Structural equation modeling using soil total nitrogen (TN), mean annual precipitation, mean annual temperature, thermal amplitude and total soil carbon as most available predictor variables explained up to 50% of the spatial variance in phosphatase activity. In this analysis, Porg could not be tested and among the rest of available variables, TN was the most important factor explaining the observed spatial gradients in phosphatase activity. On the other hand, phosphatase activity was also found to be associated with climatic conditions and soil type across different biomes worldwide. The close association among different predictors like Porg, TN and precipitation suggest that P recycling is driven by a broad scale pattern of ecosystem productivity capacity.
Collapse
Affiliation(s)
- O Margalef
- CSIC, Global Ecology Unit CREAF-CSIC-UAB, Bellaterra, 08193, Catalonia, Spain.
- CREAF, Cerdanyola del Vallès, 08193, Catalonia, Spain.
| | - J Sardans
- CSIC, Global Ecology Unit CREAF-CSIC-UAB, Bellaterra, 08193, Catalonia, Spain
- CREAF, Cerdanyola del Vallès, 08193, Catalonia, Spain
| | - M Fernández-Martínez
- CSIC, Global Ecology Unit CREAF-CSIC-UAB, Bellaterra, 08193, Catalonia, Spain
- CREAF, Cerdanyola del Vallès, 08193, Catalonia, Spain
| | | | - I A Janssens
- Department of Biology, University of Antwerp, Universiteitsplein 1, B‑2610, Wilrijk, Belgium
| | - P Ciais
- Laboratoire des Sciences du Climat et de l'Environnement, IPSL-LSCE CEA CNRS UVSQ UPSaclay, 91190, Gif-sur-Yvette, France
| | - D Goll
- Laboratoire des Sciences du Climat et de l'Environnement, IPSL-LSCE CEA CNRS UVSQ UPSaclay, 91190, Gif-sur-Yvette, France
| | - A Richter
- Department of Microbiology and Ecosystem Science, University of Vienna, Vienna, A‑1090, Austria
| | - M Obersteiner
- International Institute for Applied Systems Analysis (IIASA), Ecosystem s Services and Management, Schlossplatz 1, A-2361, Laxenburg, Austria
| | - D Asensio
- CSIC, Global Ecology Unit CREAF-CSIC-UAB, Bellaterra, 08193, Catalonia, Spain
- CREAF, Cerdanyola del Vallès, 08193, Catalonia, Spain
| | - J Peñuelas
- CSIC, Global Ecology Unit CREAF-CSIC-UAB, Bellaterra, 08193, Catalonia, Spain
- CREAF, Cerdanyola del Vallès, 08193, Catalonia, Spain
| |
Collapse
|
5
|
Peñuelas J, Asensio D, Tholl D, Wenke K, Rosenkranz M, Piechulla B, Schnitzler JP. Biogenic volatile emissions from the soil. Plant Cell Environ 2014; 37:1866-91. [PMID: 24689847 DOI: 10.1111/pce.12340] [Citation(s) in RCA: 146] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2013] [Revised: 03/10/2014] [Accepted: 03/14/2014] [Indexed: 05/18/2023]
Abstract
Volatile compounds are usually associated with an appearance/presence in the atmosphere. Recent advances, however, indicated that the soil is a huge reservoir and source of biogenic volatile organic compounds (bVOCs), which are formed from decomposing litter and dead organic material or are synthesized by underground living organism or organs and tissues of plants. This review summarizes the scarce available data on the exchange of VOCs between soil and atmosphere and the features of the soil and particle structure allowing diffusion of volatiles in the soil, which is the prerequisite for biological VOC-based interactions. In fact, soil may function either as a sink or as a source of bVOCs. Soil VOC emissions to the atmosphere are often 1-2 (0-3) orders of magnitude lower than those from aboveground vegetation. Microorganisms and the plant root system are the major sources for bVOCs. The current methodology to detect belowground volatiles is described as well as the metabolic capabilities resulting in the wealth of microbial and root VOC emissions. Furthermore, VOC profiles are discussed as non-destructive fingerprints for the detection of organisms. In the last chapter, belowground volatile-based bi- and multi-trophic interactions between microorganisms, plants and invertebrates in the soil are discussed.
Collapse
Affiliation(s)
- J Peñuelas
- Global Ecology Unit CREAF-CEAB-CSIC-UAB, CSIC, Catalonia, Spain; CREAF, Catalonia, Spain
| | | | | | | | | | | | | |
Collapse
|
6
|
Vega-Villegas ME, Galán-Guzmán MC, Gallego-Plazas J, Cervantes A, Escudero P, Tabernero J, Massutí B, Alonso-Orduña V, Asensio D, Rivera F. Phase II trial of preoperative irinotecan-cisplatin (IC) followed by concurrent IC and radiotherapy (IC/RT) for locally advanced gastric and esophago-gastric junction adenocarcinoma (LA-G/EGJ-A). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4059 Background: Long-term survival for LA-G/EGJ-A is poor and could be improved by preoperative chemoradiotherapy. We performed a phase II trial to evaluate IC followed by IC/RT in this setting. Methods: Patients with locally advanced (stage II-IV, M0) G/EGJ-A were included. Main objective was pathological complete response (pCR). Secondary objectives were toxicity, response to preoperative treatment and resection rate. Pretreatment staging included an esophagogram, EUS and CT scan. Two courses of IC (Irinotecan 65mg/m2 and Cisplatin 30mg/m2 d 1 and 8, each 21 d) were given and pts without progression received IC/RT: daily RT (180cGy fractions, total dose: 5040cGy) with concurrent IC (Irinotecan 65mg/m2 and Cisplatin 30mg/m2 d 1, 8, 15 and 22 of RT). Response to preoperative treatment was evaluated with EUS and CT scan 3–4 weeks after the end of radiotherapy. Five to 8 weeks after RT, surgical resection was performed if feasible. Results: Between 2003 and 2005, 40 pts were included: 32 men; median age 65 (45–80); PS (ECOG): 0: 38%, 1: 59%, 2: 3%; Location and resectability: Esophago-gastric Junction: 16 pts (resectable: 11 pts), Stomach: 24 pts (resectable: 13 pts); Stage: II: 13 pts, III: 15 pts, IV: 12 pts. Grade 3–4 toxicity of IC (40 pts evaluable): neutropenia 22 % (febrile 5%), diarrhoea 8%, emesis 5%, asthenia 3%. One pt (3%) died during IC due to progression. All the 33 pts who received IC/RT were evaluable for toxicity (G-3–4): neutropenia 39% (febrile 0%), diarrhoea 0%, emesis 6%, asthenia 26%, thrombocytopenia 6%. Four pts (12%) died during IC/RT (toxicity: 2 pts, progression: 2 pts). Response to preoperative treatment: PR: 6 pts, SD: 21 pts, Prog: 6 pts, No Evaluated: 7 pts. R0 resections were performed in 12 out of 24 (50%) initially resectable pts (pCR: 2 pts) and in 4 out of 16 (25%) initially non-resectable pts (pCR: 0 pts). One pt died during the first 30 days after resection. With a median follow-up of 12 months, 16 pts (40%) are alive with disease, 10 (25%) pts are alive and disease free and 14 pts (35%) have died. Conclusions: Preoperative IC> IC/RT obtained moderate response and resection rates with mild toxicity in LA-G/EGJ-A. Supported by a grant from Prasfarma/Almirall Prodesfarma. [Table: see text]
Collapse
Affiliation(s)
- M. E. Vega-Villegas
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - M. C. Galán-Guzmán
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - J. Gallego-Plazas
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - A. Cervantes
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - P. Escudero
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - J. Tabernero
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - B. Massutí
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - V. Alonso-Orduña
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - D. Asensio
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| | - F. Rivera
- HU M Valdecilla, Santander, Spain; ICO, Barcelona, Spain; H. General U, Elche, Spain; H. Clinico U., Valencia, Spain; H. Clinico U. Lozano Blesa, Zaragoza, Spain; H.G.U. Valle de Hebrón, Barcelona, Spain; H. General U, Alicante, Spain; H. Miguel Servet, Zaragoza, Spain; Prasfarma/Almirall Prodesfarma, Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain
| |
Collapse
|
7
|
Saigi E, Batiste-Alentorn E, Diaz N, Galan A, Salud A, Campos JM, Losa F, Gallen M, Massuti B, Asensio D. Phase II study of weekly irinotecan (CPT-11) associated to protracted oral tegafur (TGF) in previously untreated, advanced colorectal cancer (ACRC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Saigi
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - E. Batiste-Alentorn
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - N. Diaz
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - A. Galan
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - A. Salud
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - J. M. Campos
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - F. Losa
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - M. Gallen
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - B. Massuti
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| | - D. Asensio
- Consorci Sanitari Parc Tauli, Sabadell, Spain; Hosp Gen de Vic, Vic, Spain; Hosp Virgen de la Arreixaca, El Palmar, Spain; Hosp de Sagunto, Puerto de Sagunto, Spain; Hosp Univ Arnau de Vilanova, Lleida, Spain; Hosp Arnau de Vilanova, Valencia, Spain; Hosp de L’Hospitalet, L’Hospitalet, Spain; Hosp del Mar, Barcelona, Spain; Hosp Gen Univ de Alicante, Alicante, Spain; Prasfarma/Almirall, Barcelona, Spain
| |
Collapse
|
8
|
Fernandez-Martos C, Aparicio J, Vicent JM, Maestu I, Llorca C, Busquier I, Campos JM, Asensio D, Romero R. Biweekly alternating FOLFOX and FOLFIRI in patients with previously untreated, advanced colorectal cancer (ACC): Updated results. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Fernandez-Martos
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - J. Aparicio
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - J. M. Vicent
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - I. Maestu
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - C. Llorca
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - I. Busquier
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - J. M. Campos
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - D. Asensio
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| | - R. Romero
- Instituto Valenciano de Oncologia, Valencia, Spain; Hospital Universitario de la Fe, Valencia, Spain; Hospital General Universitario de Valencia, Valencia, Spain; Hospital Virgen de los Lirios, Alicante, Spain; Hospital General de Elda, Alicante, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Prasfarma/Almirall, Barcelona, Spain; Recerca Clinica, Barcelona, Spain
| |
Collapse
|
9
|
Dotor E, Navarro M, Vega ME, Sánchez-Rovira P, Cervantes A, García JL, Suárez M, Aranda E, Asensio D, García A. Irinotecan (CPT-11) and 5-fluorouracil (5-FU) concomitantly with preoperative radiotherapy (RT) in patients (pts) with locally advanced resectable rectal cancer. Updated results of a phase II study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- E. Dotor
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - M. Navarro
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - M. E. Vega
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - P. Sánchez-Rovira
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - A. Cervantes
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - J. L. García
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - M. Suárez
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - E. Aranda
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - D. Asensio
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| | - A. García
- Instituto Catalán de Oncología, Hospitalet de Llobregat-Barcelona, Spain; Hospital Marqués de Valdecilla, Santander, Spain; Hospital Ciudad de Jaén, Jaén, Spain; Hospital Clínico de Valencia, Valencia, Spain; Hospital Ramón y Cajal, Madrid, Spain; Hospital del Mar, Barcelona, Spain; Hospital Reina Sofía, Córdoba, Spain; Prasfarma / Almirall, Barcelona, Spain; Aventis Pharma, S.A., Madrid, Spain
| |
Collapse
|
10
|
Barrueco M, Vicente M, López I, Gonsalves T, Terrero D, García J, Asensio D. [Smoking of school children in rural Castilla-León environment. Attitudes of the school population]. Arch Bronconeumol 1995; 31:23-7. [PMID: 7881711 DOI: 10.1016/s0300-2896(15)30983-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Tobacco smoking is the most important health problem among school-age children and educational programs aiming at prevention must be taken up by all members of the school community (parents, teachers and students) as well as by health providers. We designed an anti-smoking campaign lasting three years directed towards sixth, seventh and eight-grade elementary school students and secondary school pupils attending classes in the area of Vitigudino (Salamanca). We report the results of student attitude surveys done at the beginning of the program. Sixty-eight percent of boys and 50.7% of girls have smoked at some time. The average age of first contact with tobacco was 12.1 +/- 2.4 years, with boys starting to smoke at a significantly younger age (p < 0.001) than girls. At present, 13.7% of school children smoke. The main reasons given for starting to smoke were that friends smoked (56.9%) and curiosity (55.4%). Tobacco smoking in the family was mentioned by only 29.5% of the students surveyed. Knowledge of medical problems related to smoking was limited. Intention to smoke upon leaving school was reported by 9%, while 46.7% did not know if they would smoke. The fact that only 44.1% of school children believe they will not smoke upon leaving school highlights the need to provide support information that will help students abstain. Programs aimed at school children have been shown to help reduce tobacco smoking in this population. An adolescent who learns to avoid tobacco is unlikely to be a smoker in adulthood.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- M Barrueco
- Servicio de Neumología, Hospital Universitario, Salamanca
| | | | | | | | | | | | | |
Collapse
|